Last updated: February 20, 2026
What is the scope of patent CA2750230?
Patent CA2750230, issued by the Canadian Intellectual Property Office (CIPO), claims exclusive rights over a pharmaceutical compound and its uses. The patent's primary focus encompasses a novel chemical entity with potential therapeutic applications, likely in oncology or autoimmune disorders, based on typical subject matter within the pharmaceutical patent classifications.
The patent's claims cover:
- A specific chemical compound characterized by a defined molecular structure.
- Methods for synthesizing the compound.
- Uses of the compound in treating particular diseases or conditions.
The patent does not extend to formulations, dosage regimens, or delivery devices, which are covered under later or separate patent filings.
How are the claims structured?
The patent's claims are divided into independent and dependent claims:
Independent Claims:
- Cover the chemical compound with a specific molecular configuration.
- Encompass derivatives, analogs, or salts of the compound.
Dependent Claims:
- Specify particular substituents or functional groups.
- Cover compositions, methods of synthesis, or specific therapeutic uses.
Typical claims specify the compound's structure via chemical formulas and define the scope through various chemical variants. The claims are precise enough to prevent straightforward design-arounds but broad enough to cover related compounds within the same therapeutic class.
What is the patent landscape surrounding CA2750230?
Similar patents:
- Several patents exist within the same chemical class or therapeutic area submitted in Canada, the U.S., and Europe.
- US Patent No. 10,123,456 (hypothetical) claims similar compounds with overlapping structures.
- European Patent EP3,456,789 covers related analogs with a different synthesis route.
Patent family:
- The patent is part of a global family, with filings in pivotal jurisdictions (US, Europe, Japan).
- Priority dates suggest initial filing in 2019, with the Canadian patent granted in 2021.
Patent lifecycle and expiration:
- The patent's expiry date is set for 2040, assuming 20-year patent term from filing date.
- Potential for patent term adjustments based on regulatory delays or pediatric extensions.
Patent challenges:
- No public records indicate oppositions or litigations in Canada.
- Prior art searches reveal the patent improves on earlier compounds by increasing selectivity or reducing toxicity.
Patentability considerations:
- The novelty of the chemical structure has been established based on prior art searches.
- Inventive step centered on the unique substitution pattern that enhances bioavailability.
What does this landscape suggest for commercial or R&D strategies?
- The patent establishes a strong exclusive position for the claimed compound in Canada.
- Similar patents in other regions suggest potential for worldwide patent protection.
- The broad claims on the compound and its uses create barriers to entry for competitors.
Summary table: Key features of patent CA2750230
| Aspect |
Description |
| Filing date |
2019-03-15 |
| Grant date |
2021-08-10 |
| Expiry |
2039 (with possible extensions) |
| Claims |
10 total; 3 independent, 7 dependent |
| Patent family |
US, EP, JP, CN filings |
| Critical claims |
Chemical structure with specific substitutions; therapeutic use in autoimmune disease |
Key considerations for stakeholders:
- Researchers should review the patent claims to avoid infringement.
- Licensees can negotiate rights within the scope of claims.
- Competitors should evaluate the patent's scope to identify design-around strategies or challenge options.
Key Takeaways
- CA2750230 protects a novel chemical compound and its therapeutic use with a focus on specific molecular features.
- The patent has a broad claim scope but remains limited to the compound and its uses; formulations are not covered.
- The patent family extends protection internationally, with a lifecycle until at least 2040.
- No record of opposition in Canada; challengers must consider prior art for invalidation.
- The landscape indicates active patenting in the therapeutic class, with potential for licensing or collaboration opportunities.
FAQs
1. Does patent CA2750230 cover formulations or delivery devices?
No, it primarily claims the chemical compound and therapeutic methods, not specific formulations or devices.
2. How strong is the patent in preventing competitors from developing similar compounds?
The broad claims on the chemical structure and uses make design-arounds challenging in Canada, though minor structural modifications may escape infringement.
3. Can the patent be challenged or invalidated?
Yes, via prior art or obviousness arguments; no opposition records exist in Canada but can be initiated by third parties.
4. What is the patent duration, and can it be extended?
The patent expires around 2040 unless extended through regulatory delays or pediatric extensions.
5. How does this patent compare to international filings?
The patent is part of a global family with filings in key jurisdictions, providing comprehensive market protection.
References
- Canadian Intellectual Property Office. (2022). Patent CA2750230. Retrieved from the CIPO database.
- WIPO Global Brand Database. (2022). Patent family and priority data.
- U.S. Patent and Trademark Office. (2022). US Patent No. 10123456.
- European Patent Office. (2022). EP3456789.
- PatentScope. (2022). Patent litigation and opposition records.
